

16 August 2011

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Single technology appraisal (STA)**

**Invitation to participate**

**Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer**

Dear Consultees and Commentators

**Invitation to become a consultee for this appraisal**

The Department of Health and the Welsh Government have asked the National Institute for Health and Clinical Excellence (NICE) to conduct an appraisal of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer and provide guidance on its use in the NHS in England and Wales.

Your organisation was selected to participate in this appraisal. Please find attached the scope, matrix and scoping consultation tables for this appraisal.

This appraisal has now formally started now. However, the manufacturer of panitumumab has informed us that they will not provide an evidence submission for this appraisal.

NICE will therefore suspend this appraisal.

If you wish to be kept informed about the next steps in this appraisal, please complete the attached confidentiality agreement – Appendix E.

We will publish information about this appraisal on the NICE website. Consultees and commentators in an appraisal usually receive information in advance of its publication on our website. We will only be able to do this for consultees and commentators who return the confidentiality agreement.

Yours sincerely,

Carole Longson  
Director, Centre for Health Technology Evaluation

Appendix A - Final scope

Appendix B - Final matrix

Appendix E - Confidentiality and acknowledgment undertaking form